Abstract
The level of sphingolipids such as ceramides (Cer) are dysregulated in patients with myocardial infarction (MI), leading to increased risk of progression towards heart failure. Dihydroceramide desaturase 1 (Des-1) is the enzyme responsible for the conversion of dihydroceramide (dhCer) into Cer in the de novo sphingolipids pathway. Its role in cardiac remodelling is unknown. This study aims to investigate the effects of a novel selective Des-1 inhibitor, CIN038, on cardiac remodelling in a mouse model of ischaemia-reperfusion (IR).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
